Luo Xinmin, Zheng Renying, Zhang Jiao, He Juan, Luo Wei, Jiang Zhi, Li Qiang
Department of Radiology, People's Hospital of Yuechi County, Guang'an, Sichuan, China.
Department of Oncology, People's Hospital of Yuechi County, Guang'an, Sichuan, China.
Front Oncol. 2024 Feb 7;14:1329801. doi: 10.3389/fonc.2024.1329801. eCollection 2024.
Radiomics, an emerging field, presents a promising avenue for the accurate prediction of biomarkers in different solid cancers. Lung cancer remains a significant global health challenge, contributing substantially to cancer-related mortality. Accurate assessment of Ki-67, a marker reflecting cellular proliferation, is crucial for evaluating tumor aggressiveness and treatment responsiveness, particularly in non-small cell lung cancer (NSCLC).
A systematic review and meta-analysis conducted following the preferred reporting items for systematic review and meta-analysis of diagnostic test accuracy studies (PRISMA-DTA) guidelines. Two authors independently conducted a literature search until September 23, 2023, in PubMed, Embase, and Web of Science. The focus was on identifying radiomics studies that predict Ki-67 expression in lung cancer. We evaluated quality using both Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) and the Radiomics Quality Score (RQS) tools. For statistical analysis in the meta-analysis, we used STATA 14.2 to assess sensitivity, specificity, heterogeneity, and diagnostic values.
Ten retrospective studies were pooled in the meta-analysis. The findings demonstrated that the use of computed tomography (CT) scan-based radiomics for predicting Ki-67 expression in lung cancer exhibited encouraging diagnostic performance. Pooled sensitivity, specificity, and area under the curve (AUC) in training cohorts were 0.78, 0.81, and 0.85, respectively. In validation cohorts, these values were 0.78, 0.70, and 0.81. Quality assessment using QUADAS-2 and RQS indicated generally acceptable study quality. Heterogeneity in training cohorts, attributed to factors like contrast-enhanced CT scans and specific Ki-67 thresholds, was observed. Notably, publication bias was detected in the training cohort, indicating that positive results are more likely to be published than non-significant or negative results. Thus, journals are encouraged to publish negative results as well.
In summary, CT-based radiomics exhibit promise in predicting Ki-67 expression in lung cancer. While the results suggest potential clinical utility, additional research efforts should concentrate on enhancing diagnostic accuracy. This could pave the way for the integration of radiomics methods as a less invasive alternative to current procedures like biopsy and surgery in the assessment of Ki-67 expression.
放射组学作为一个新兴领域,为准确预测不同实体癌中的生物标志物提供了一条有前景的途径。肺癌仍然是一项重大的全球健康挑战,对癌症相关死亡率有重大影响。准确评估Ki-67(一种反映细胞增殖的标志物)对于评估肿瘤侵袭性和治疗反应性至关重要,尤其是在非小细胞肺癌(NSCLC)中。
按照诊断试验准确性研究的系统评价和Meta分析的首选报告项目(PRISMA-DTA)指南进行系统评价和Meta分析。两位作者独立进行文献检索,截至2023年9月23日,检索了PubMed、Embase和Web of Science。重点是识别预测肺癌中Ki-67表达的放射组学研究。我们使用诊断准确性研究质量评估(QUADAS-2)和放射组学质量评分(RQS)工具评估质量。在Meta分析中进行统计分析时,我们使用STATA 14.2来评估敏感性、特异性、异质性和诊断价值。
Meta分析纳入了10项回顾性研究。结果表明,基于计算机断层扫描(CT)的放射组学用于预测肺癌中的Ki-67表达表现出令人鼓舞的诊断性能。训练队列中的合并敏感性、特异性和曲线下面积(AUC)分别为0.78、0.81和0.85。在验证队列中,这些值分别为0.78、0.70和0.81。使用QUADAS-2和RQS进行质量评估表明研究质量总体上可以接受。观察到训练队列中的异质性,其归因于对比增强CT扫描和特定的Ki-67阈值等因素。值得注意的是,在训练队列中检测到发表偏倚,这表明阳性结果比无统计学意义或阴性结果更有可能发表。因此,鼓励期刊也发表阴性结果。
总之,基于CT的放射组学在预测肺癌中的Ki-67表达方面显示出前景。虽然结果表明具有潜在的临床应用价值,但更多的研究工作应集中在提高诊断准确性上。这可能为将放射组学方法整合为一种侵入性较小的替代方法铺平道路,以替代目前在评估Ki-67表达时使用的活检和手术等程序。